Knockdown Survivin Expression Reduces the Efficacy of Curcumin Treatment in Hepatocellular Carcinoma Cells

详细信息    查看全文

• 作者：Chin-Sheng Hung MD (1) (2) (3) (4)
  Hui-Hsiung Liu MD ; PhD (5)
  Ming-Te Huang MD (1) (2) (3) (6)
  Chao-Wen Cheng PhD (1)
  Li-Jen Kuo MD (1) (2) (3) (4)
  Yuan-Soon Ho PhD (7) (8)
  Chih-Hsiung Wu MD ; PhD (1) (2) (3) (6)
  Chien-Ming Chen MS (8)
  Po-Li Wei MD ; PhD (1) (2) (3) (4)
  Yu-Jia Chang PhD (1) (2) (3) (4) (7)
  
• 刊名：Annals of Surgical Oncology
• 出版年：2012
• 出版时间：October 2012
• 年：2012
• 卷：19
• 期：11
• 页码：3547-3555
• 全文大小：731KB
• 参考文献：1. Bruix J, Boix L, Sala M, Llovet JM. Focus on hepatocellular carcinoma. / Cancer Cell. 2004;5:215鈥?. CrossRef
  2. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. / Lancet. 2003;362:1907鈥?7. CrossRef
  3. Thomas MB, Zhu AX. Hepatocellular carcinoma: the need for progress. / J Clin Oncol. 2005;23:2892鈥?. CrossRef
  4. Bruix J, Llovet JM. Major achievements in hepatocellular carcinoma. / Lancet. 2009;373:614鈥?. CrossRef
  5. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. / Nat Med. 1997;3:917鈥?1. CrossRef
  6. Reed JC. The survivin saga goes in vivo. / J Clin Invest. 2001;108:965鈥?. CrossRef
  7. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. / Nature. 1998;396:580鈥?. CrossRef
  8. Chandele A, Prasad V, Jagtap JC, Shukla R, Shastry PR. Upregulation of survivin in G2/M cells and inhibition of caspase 9 activity enhances resistance in staurosporine-induced apoptosis. / Neoplasia. 2004;6:29鈥?0.
  9. Fields AC, Cotsonis G, Sexton D, Santoianni R, Cohen C. Survivin expression in hepatocellular carcinoma: correlation with proliferation, prognostic parameters, and outcome. / Mod Pathol. 2004;17:1378鈥?5. CrossRef
  10. Augello C, Caruso L, Maggioni M, Donadon M, Montorsi M, Santambrogio R, et al. Inhibitors of apoptosis proteins (IAPs) expression and their prognostic significance in hepatocellular carcinoma. / BMC Cancer. 2009;9:125. CrossRef
  11. Huang MT, Wei PL, Liu JJ, Liu DZ, Huey-Chun H, An J, et al. Knockdown of thrombomodulin enhances HCC cell migration through increase of ZEB1 and decrease of E-cadherin gene expression. / Ann Surg Oncol. 2010;17:3379鈥?5. CrossRef
  12. Zhang T, Ding X, Wei D, Cheng P, Su X, Liu H, et al. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. / Anticancer Drugs. 2010;21:326鈥?2. CrossRef
  13. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma. / Blood. 2003;101:1535鈥?2. CrossRef
  14. Kanda N, Seno H, Konda Y, Marusawa H, Kanai M, Nakajima T, et al. STAT3 is constitutively activated and supports cell survival in association with survivin expression in gastric cancer cells. / Oncogene. 2004;23:4921鈥?. CrossRef
  15. Fuke H, Shiraki K, Sugimoto K, Tanaka J, Beppu T, Yoneda K, et al. Jak inhibitor induces S phase cell-cycle arrest and augments TRAIL-induced apoptosis in human hepatocellular carcinoma cells. / Biochem Biophys Res Commun. 2007;363:738鈥?4. CrossRef
  16. Anand P, Sundaram C, Jhurani S, Kunnumakkara AB, Aggarwal BB. Curcumin and cancer: an 鈥渙ld-age鈥?disease with an 鈥渁ge-old鈥?solution. / Cancer Lett. 2008;267:133鈥?4. CrossRef
  17. Shishodia S, Singh T, Chaturvedi MM. Modulation of transcription factors by curcumin. / Adv Exp Med Biol. 2007;595:127鈥?8. CrossRef
  18. Ravindran J, Prasad S, Aggarwal BB. Curcumin and cancer cells: how many ways can curry kill tumor cells selectively? / AAPS J. 2009;11:495鈥?10. CrossRef
  19. Johnson JJ, Mukhtar H. Curcumin for chemoprevention of colon cancer. / Cancer Lett. 2007;255:170鈥?1. CrossRef
  20. Glienke W, Maute L, Wicht J, Bergmann L. Curcumin inhibits constitutive STAT3 phosphorylation in human pancreatic cancer cell lines and downregulation of survivin/BIRC5 gene expression. / Cancer Invest. 2010;28:166鈥?1. CrossRef
  21. Chang YJ, Tai CJ, Kuo LJ, Wei PL, Liang HH, Liu TZ, et al. Glucose-regulated protein 78 (GRP78) mediated the efficacy to curcumin treatment on hepatocellular carcinoma. / Ann Surg Oncol. 2011;18:2395鈥?03. CrossRef
  22. Chang YJ, Chiu CC, Wu CH, An J, Wu CC, Liu TZ, et al. Glucose-regulated protein 78 (GRP78) silencing enhances cell migration but does not influence cell proliferation in hepatocellular carcinoma. / Ann Surg Oncol. 2010;17:1703鈥?. CrossRef
  23. Chiou JF, Tai CJ, Huang MT, Wei PL, Wang YH, An J, et al. Glucose-regulated protein 78 is a novel contributor to acquisition of resistance to sorafenib in hepatocellular carcinoma. / Ann Surg Oncol. 2010;17:603鈥?2. CrossRef
  24. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. / Lancet Oncol. 2009;10:25鈥?4. CrossRef
  25. Wang SK, Liang PH, Astronomo RD, Hsu TL, Hsieh SL, Burton DR, et al. Targeting the carbohydrates on HIV-1: interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. / Proc Natl Acad Sci USA. 2008;105:3690鈥?. CrossRef
  26. Sowinski S, Jolly C, Berninghausen O, Purbhoo MA, Chauveau A, K枚hler K, et al. Membrane nanotubes physically connect T cells over long distances presenting a novel route for HIV-1 transmission. / Nat Cell Biol. 2008;10:211鈥?. CrossRef
  27. Monzo M, Rosell R, Felip E, Astudillo J, S谩nchez JJ, Maestre J, et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. / J Clin Oncol. 1999;17:2100鈥?.
  28. Satoh K, Kaneko K, Hirota M, Masamune A, Satoh A, Shimosegawa T. Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer. / Pancreas. 2001;23:251鈥?. CrossRef
  29. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. / Cancer Res. 1998;58:5071鈥?.
  30. Tai CJ, Chin-Sheng H, Kuo LJ, Wei PL, Lu HH, Chen HA, et al. Survivin-mediated cancer cell migration through GRP78 and epithelial-mesenchymal transition (EMT) marker expression in Mahlavu cells. / Ann Surg Oncol. 2012;19:336鈥?3. CrossRef
  31. Watson JL, Greenshields A, Hill R, Hilchie A, Lee PW, Giacomantonio CA, et al. Curcumin-induced apoptosis in ovarian carcinoma cells is p53-independent and involves p38 mitogen-activated protein kinase activation and downregulation of Bcl-2 and survivin expression and Akt signaling. / Mol Carcinog. 2010;49:13鈥?4.
  32. Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. / J Clin Oncol. 2009;27:2091鈥?. CrossRef
  33. Dean-Colomb W, Esteva FJ. Her2-positive breast cancer: herceptin and beyond. / Eur J Cancer. 2008;44:2806鈥?2. CrossRef
  
• 作者单位：Chin-Sheng Hung MD (1) (2) (3) (4)
  Hui-Hsiung Liu MD, PhD (5)
  Ming-Te Huang MD (1) (2) (3) (6)
  Chao-Wen Cheng PhD (1)
  Li-Jen Kuo MD (1) (2) (3) (4)
  Yuan-Soon Ho PhD (7) (8)
  Chih-Hsiung Wu MD, PhD (1) (2) (3) (6)
  Chien-Ming Chen MS (8)
  Po-Li Wei MD, PhD (1) (2) (3) (4)
  Yu-Jia Chang PhD (1) (2) (3) (4) (7)
  
  1. Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
  2. Department of Surgery, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan
  3. Division of General Surgery, Department of Surgery, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan
  4. Cancer Research Center, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan
  5. Department of Public Health, School of Public Health, Taipei Medical University, Taiwan, Taipei, Taiwan
  6. Division of General Surgery, Department of Surgery, Shuang Ho Hospital, Taipei Medical University, Taipei, Taiwan
  7. Center of Excellence for Cancer Research, Taipei Medical University, Taipei, Taiwan
  8. School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan
  

文摘

Background Survivin is a potential therapeutic target for cancer. Increased survivin expression promotes cell survival and therapeutic resistance. However, there is little information regarding whether the expression level of survivin affects curcumin treatment in hepatocellular carcinoma (HCC). Methods Survivin expression was suppressed in HCC cells using a short interfering RNA (siRNA) technique. The anticancer effects of curcumin were examined using a biosensor system, MTT assay, TUNEL assay, and cell cycle analysis. Results Curcumin resistance developed in cells with suppressed survivin, in contrast to the parental cells, as determined by survival assays. Cell cycle analysis and TUNEL assays revealed that the apoptotic cell population was increased in the scrambled-siRNA cells treated with curcumin compared with the survivin-siRNA cells. Suppression of survivin expression resulted in curcumin resistance via the modulation of Bcl-2 and Bax expression. Conclusions We conclude that the expression levels of survivin may mediate the therapeutic efficacy of curcumin in HCC cells.